hadrontherapy is an innovative form of radiotherapy , based on high - technology equipment using proton or carbon ions beams to destroy tumours [ 1 , 2 ] .
this treatment method enables significantly higher ballistic precision to be achieved , compared to photons ( x - rays ) with , as expected therapeutic benefit , an improvement of quality of life and chances of recovery .
carbon ions are also specifically characterised by superior biological efficacy ( relative biological effectiveness from 1.5 to 3 ) , overcoming the radiation resistance of certain cancers to photons and even protons .
indeed , carbon ion beams when compared to x - rays represent a distinct advantage for the treatment of highly radiation - resistant tumours .
an initial study assessing recruitment potential for proton therapy was conducted in 1998 in italy , showing an incidence of 10  825 cases / year .
one year later , a second study was carried out in the context of the medaustron project for the construction of a carbon ions therapy centre in austria . considering patients living in austria and neighbouring countries ,
the patient recruitment potential ( proton and carbon ) was estimated with an incidence of 13  145 cases / year . in france , in 2002 , a third study was conducted in the context of the etoile medical project .
this study revealed an annual incidence of approximately 5320 cases / year for carbon ions .
concomitantly , a fourth study was conducted , again in the context of the medaustron project , estimating the incidence of cases eligible for hadrontherapy in austria at 2044 cases / year .
finally , again in 2002 , in the context of the project for the construction of the cnao centre in italy , an epidemiological study was conducted , estimating the incidence of cases eligible for carbon therapy at 3694 cases / year and proton therapy at 1885 cases / year . .
since 2004 , no other epidemiological studies have been published for hadrontherapy . in 2011 , however , the japanese team from the national institute for radiological sciences ( nirs ) , pioneer in carbon therapy , published the results of its 1994 to 2011 clinical activity .
patients were included in clinical trials and the number of patients receiving carbon therapy was 6157 .
this value is the incidence of treated cases , over 17 years without any notion of recruitment potential and with a rather slow ramp up of the activity .  
a list of priority indications that can be treated by hadrontherapy ( table 1 ) was drawn up by the gcs etoile medical group , in collaboration with national and international experts , based on published data ranked using an  evidence - based medicine
this literature review was based on provided or expected medical service criteria ( survival and quality of life ) . according to the classification used by the european survey group of rare diseases , the eligible tumours that can be treated by hadrontherapy conform to the criteria of rare diseases based on the following thresholds of epidemiological indicators : prevalence  50 cases/100  000 persons within a given population and incidence  6 cases/100  000 persons / year .
indeed , for all tumor types identified during the previous hadrontherapy epidemiological studies [ 58 ] , the calculated and cumulative incidences are all below these thresholds ( table 2 ) . amongst the hadrontherapy indications , 25 are tumours listed in the orphanet international database of rare diseases   ( cf .
the exact incidence of each disease eligible for hadrontherapy is difficult to determine from the available resources .
indeed , the published data [ 513 ] pertain to series of patients for which the aim was not to assess the level of demand for treatment .
these were rather series of patients who had received the therapy , but whose recruitment had not been accounted for in tumour registries .
considering the scarcity and specific nature of the tumours concerned by hadrontherapy , it is difficult to extrapolate and assess the treatment demand from these results .
hadrontherapy indications are defined according to anatomical location of the tumours , clinical stage , pathology , therapeutic alternatives ( e.g. , surgical contraindications ) , and patient characteristics ( general condition and comorbidities ) .
french cancer registries record data required to estimate cancer incidence but fail to provide sufficient detail of the tumour stage or of therapeutic data . moreover , the registries cover only approximately 15% of the french population and mainly for the most frequent cancers .
therefore , these registries do not allow the incidence of these tumours to be estimated .
this regional study will provide us with more detailed figures concerning the potential number of new cases eligible for hadrontherapy , allowing us to better adapt the future care offer delivered by the national hadrontherapy centre .
this survey should also provide us with information on certain medical indicators to assist in the design of future hadrontherapy clinical trials ( detailed incidence data , patient population characteristics , tumour stages , recruitment pools , etc . ) .
finally , this epidemiological field study is also eventually intended to be used to organise a network of highly specialised cares . according to the first epidemiological study carried out in france , in association with ( i ) the results of the literature review that defined the list of hadrontherapy indications and ( ii ) the indications chosen for proton therapy in france
, the number of cases in the rhne - alpes region eligible for hadrontherapy is estimated at 200 per year ( the rhne - alpes region is home to 10% of the french population ) .
the main goal is to asses , within the rhne - alpes region , the incidence of cancers with hadrontherapy indication .
the secondary goals are ( 1 ) to characterise the affected population , ( 2 ) to describe the characteristics of the observed cancers , and ( 3 ) to describe the characteristics of the treatments implemented when hadrontherapy is unavailable .
this is a prospective , multicentre incidence study , lasting 24 months , conducted with the rcp ( runion de concertation pluridisciplinaire 
multidisciplinary tumor board ) groups of the rhne - alpes region in france , that offer a therapeutic strategy for cancers for which hadrontherapy is an alternative . 

this study required the involvement of a part - time consultant epidemiology engineer , who totalled one woman - year of work to provide ( 1 ) phone canvassing to identify and involve regional cancer research players ; ( 2 ) the protocol construction and testing phase , along with the data collection tools ; ( 3 ) meetings with 3c ( cancer coordination centres ) coordinators and rcps ; ( 4 ) investigator centres inclusion meetings .
these included year of birth ; gender ; patient 's department of residence ; world health organization ( who ) performance status , patient 's therapeutic status : initial stage or recurrence ; initial staging ( uicc tnm classification : international union against cancer ) ; treatments received before recurrence ; time to recurrence ; staging at time of current tumour management ; icd-10 ( international classification of diseases ) ; icdo ( international classification of diseases for oncology ) histological type ; site of surgery and margin quality ; postsurgical histopathological stage ( ptnm stage ) ; prior radiotherapy ; proposed treatment . 

the criteria included adults and children , no age limit , and patients presenting with hadrontherapy indications listed in table 1 , whose medical files have been discussed by experts during an rcp .
compatible general and psychological condition refers to patients not suffering from life - threatening comorbidities ( no acute or chronic diseases whose short - term lethal risk is dominant relative to the cancer ) , capable of adhering to a disease monitoring protocol and of understanding and accepting a complex treatment requiring close cooperation and staying for several days away from home .  
  tumour  inclusion criteria .
these include unresectable tumour , belonging to a known radiation - resistant pathological group , mainly in a locoregional development stage , recurrent or local relapse , with low metastatic potential or m+ dissemination ( presence of one or more remote metastases at the time of diagnosis ) presenting a low threat ( slow development and/or metastases that can be readily treated ) .
these inclusion criteria are the results of a consensus synthesis of a systematic literature review performed during 8 years , pathology by pathology with the participation of about one hundred of european medical , surgical , and radiation oncologists , managed by physicians trained in hadrontherapy ( mainly protontherapy ) .
the review was carried out by an academic laboratory specialized in clinical trial setup and analysis and was made according to the  evidence - based medicine 
definition of  tumour  inclusion criteria 

 radiation resistance : tumour which estimated local dose required for local control that is higher that the maximum acceptable dose equivalent ( mpde ) for surrounding organs necessarily irradiated under applicable technical conditions , assessed by a radiation oncologist ( guide des procdures de radiothrapie externe 2007 ( guidelines for external radiotherapy procedures ) ; joint effort by the french society for oncology radiotherapy ( socit franaise de radiothrapie oncologique  sfro ) , and the french society for medical physics ( socit franaise de physique mdicale  sfpm ) , conducted in collaboration with the representatives of the french association of electroradiology paramedical workers ( association franaise du personnel paramdical d'electroradiologie  afppe ) ) . 

unresectable : tumour which local or locoregional expansion stage renders excision either is technically impossible ( opinion of an experienced surgical team ) or surgically unacceptable due to the irreparable damage that would be necessary ( cancer : principles & practice of oncology 2005 ; devita , v. general articles on treatment strategies in cancer ) . 

locoregional : it refers to the tumour expansion state corresponding to the anatomical diffusion region of the primary tumour by contiguous expansion ( t of tnm ) and/or by lymphatic diffusion , maintaining a rank of n in tnm staging , in other words , any tumour at stage m0 ( latest edition of the tumour tnm classification published by the ( uicc ) international union against cancer or the ( ajc ) american joint committee for cancer staging ) . 

low metastatic potential : m0 situations whose medium - term ( 5-year ) metastatic risk is considered to be sufficiently low to justify curative locoregional treatment involving significant means .
this threshold is difficult to determine ; a level greater than 50% seems unreasonable . as an example ,
nonthreatening m+ dissemination or controlled by medical treatments : this means the presence of one or more remote metastases at the time of diagnosis , presenting no immediate threat as displaying slow development and/or accessible to effective treatment ( typical case of some low - grade sarcomas lung metastases ) .
these situations are indicative of locoregional disease treatment using complex and expensive techniques such as hadrontherapy . 

local relapse or local recurrence ( these two terms are synonymous ) : it means the redevelopment , at the same site as initially , of a previously effectively treated tumour ( dictionary of medical terms , garnier - delamare ) . 
 

radiation resistance : tumour which estimated local dose required for local control that is higher that the maximum acceptable dose equivalent ( mpde ) for surrounding organs necessarily irradiated under applicable technical conditions , assessed by a radiation oncologist ( guide des procdures de radiothrapie externe 2007 ( guidelines for external radiotherapy procedures ) ; joint effort by the french society for oncology radiotherapy ( socit franaise de radiothrapie oncologique  sfro ) , and the french society for medical physics ( socit franaise de physique mdicale  sfpm ) , conducted in collaboration with the representatives of the french association of electroradiology paramedical workers ( association franaise du personnel paramdical d'electroradiologie  afppe ) ) . 

unresectable : tumour which local or locoregional expansion stage renders excision either is technically impossible ( opinion of an experienced surgical team ) or surgically unacceptable due to the irreparable damage that would be necessary ( cancer : principles & practice of oncology 2005 ; devita , v. general articles on treatment strategies in cancer ) . 

locoregional : it refers to the tumour expansion state corresponding to the anatomical diffusion region of the primary tumour by contiguous expansion ( t of tnm ) and/or by lymphatic diffusion , maintaining a rank of n in tnm staging , in other words , any tumour at stage m0 ( latest edition of the tumour tnm classification published by the ( uicc ) international union against cancer or the ( ajc ) american joint committee for cancer staging ) . 

low metastatic potential : m0 situations whose medium - term ( 5-year ) metastatic risk is considered to be sufficiently low to justify curative locoregional treatment involving significant means .
this threshold is difficult to determine ; a level greater than 50% seems unreasonable . as an example ,
nonthreatening m+ dissemination or controlled by medical treatments : this means the presence of one or more remote metastases at the time of diagnosis , presenting no immediate threat as displaying slow development and/or accessible to effective treatment ( typical case of some low - grade sarcomas lung metastases ) .
these situations are indicative of locoregional disease treatment using complex and expensive techniques such as hadrontherapy .  

local relapse or local recurrence ( these two terms are synonymous ) : it means the redevelopment , at the same site as initially , of a previously effectively treated tumour ( dictionary of medical terms , garnier - delamare ) . 

they are the description of the tumours and population characteristics , along with the treatments proposed and implemented by the rcps .  

those were healthcare establishments ( private and public ) in the rhne - alpes region hosting rcp groups and having radiotherapy departments . 

they consisted of groups of oncology specialists with expertise in the following diseases : musculoskeletal sarcomas and tumours , head and neck ( h and n ) , gastroenterology , paediatrics , dermatology , endocrine and central nervous system tumours . 

case screening is performed continuously by the physicians and clinical research technician in light of the list of indications ( table 1 ) , during each rcp . 

the questionnaire , along with the organisation of the investigation , was assessed beforehand by a sample population of investigators ( 3c coordinators and cras ) via a semiguided telephone interview .
for the questionnaire , the evaluation focused on general understanding , the form and length of the questionnaire , time required for completion , amount of data to collect , and the relevance of the selected criteria .
the evaluation of the investigation method pertained to the choice of individuals involved in data collection organisation , the data recording method , the organisation for data recording , and the identification source for clinical cases .  

variables are encoded in a uniform and standard manner in an investigator 's guide book , which contains detailed information concerning the definitions of each indicator to collect .
dual computer data input is performed , along with checks for missing or improbable data ( encoding errors , date inconsistencies ) . 
 statistical methods .
the incidence of cancers is expressed as the number of cases reported from the demographic figures of the rhne - alpes region over the studied period and expressed per 100,000 inhabitants .
  the study involves 13 clinical research technicians , 50 rcp coordinating physicians and 12 cancer coordination centres ( see table 3 ) .
the study mobilises 27 rhne - alpes region healthcare centres , of which 8 university hospitals , 1 regional cancer centre , 1 public - private cancer institute , 12 general hospitals , the lyon paediatric oncology hospital institute , and 4 private clinics .
this led to a sense of ownership and motivation on the part of the centres . as a whole , the study covered the region 's 11 hospital areas and involved 52 groups , out of some sixty listed , of cancer specialists with expertise in the diseases that were to identify . during the study ,
mean patient age was 43 years [ 289 ] , and men were more numerous ( or = 1.52 ) .
the highest number of cases ( 39.6% ) was in the 218 years age group .
the number of patients with recurrence was slightly lower ( 45.3% ) than the number of patients receiving initial care ( 54.7% ) .
carcinomas , sarcomas ( table 4 ) , and paediatric tumours ( table 5 ) were the most frequently identified diseases , and their locations are varied . during the rcp , radiotherapy , chemotherapy , and surgery were prescribed , respectively , in 58% , 57% , and 57% of cases .
previous treatments were chemotherapy , surgery , or conventional radiotherapy in 62.5% , 58.3% , and 58.3% of cases , respectively .
the number of cases identified during the study was approximately four times lower than the potential estimate .
( i.e. , 2.5 cases / rcp ) , and the rhne department identified 56.6% ( i.e. , 1.2 cases / rcp ) .
isre identified twice as many cases as rhne , even though it only has nine expert groups , that is , 2.6 times less than in rhne , which has 24 .
the geographic areas not covered by the study correspond to the location of 15 private healthcare centres and to the medical activity of six general and four specialist rcp groups .
the first six groups had no recruitment potential according to the statement of their coordinators .
this preliminary data collection , conducted over a one - year period , reported 53 cases of hadrontherapy indications , compared to the estimated cap of 200 cases .
the estimated incidence of cancers eligible for hadrontherapy in the rhne - alpes region in 2010 , regardless of disease , is of 8.5/100,000 inhabitants .
the diseases to identify in this study are little known , their distribution has not been studied , and we are unaware of any epidemic outbreaks . moreover , considering that the cancers to identify are rare , it is likely that the number of cases to identify per investigator centre will be very low ( estimated incidence of at the most 1 to 5 cases / year ) . finally , the primary goal of the rcp groups is to provide an immediate therapeutic solution .
case identification for an observational study is thus unusual in the context of an rcp . because of this
, sustaining team vigilance and motivation for case identification is difficult to obtain and requires regular refreshing throughout the study .
this step also served to circulate hadrontherapy information and to facilitate adhesion , ownership , and mobilisation around the project .
the individuals involved in study organisation were in charge of systematically directing each cancer patient to the elective experts .
patients suffering from diseases eligible for hadrontherapy were frequently in relapse condition and rather at the end of their therapeutic options .
this is due to the fact that these diseases have usually a slow and long evolution ; therefore , this study had more chance to catch them somewhere in an advanced stage than at the beginning .
it can also be considered that the lack of satisfactory treatment means as hadrontherapy makes these populations have more chance to show more advanced disease than it will be expected to be seen in the future .
the identification and decision to include a patient in the study were made by the rcp groups including these experts . under these conditions , we have confidence in the case orientation and identification system .
selection criterion is one of the criteria used to identify patients eligible for hadrontherapy . in our current state of knowledge
this can be explained in part by the fact that it is easier to create multidisciplinary expert groups in public hospitals and to set up clinical research . due to their structure , these establishments benefit from human resources with more varied medical specialities than in private radiotherapy practices . in all likelihood , cases eligible for hadrontherapy could have been treated by these private centres during the study and ignored .  
one should be very cautious when comparing the results of this study with those of published incidence studies .
the methodologies employed in these previous studies are heterogeneous , and/or their flow is insufficiently documented .
moreover , their goal was to estimate a recruitment potential based on the extrapolation of the results .
the methodologies used were not intended to provide information concerning an exhaustive incidence , as proposed by our study .
finally , the published studies were conducted in attractive institutions , specialising in cancer care and selected for this reason ; this may bias the assessment of prevalence . under these conditions , it is easy to confuse incidence and prevalence .
these elements could , in part , explain the observed difference between the preliminary results obtained in our study and the estimate calculated from the epidemiological results published in the literature .
only the publication of results obtained from other exhaustive epidemiological studies conducted in the same areas could support this hypothesis .  
it is unlikely that the lack of case recording associated with the medical activity of the four groups not involved in this data collection could alone explain the observed difference between the calculated incidence estimates and the preliminary results obtained . for several clinicians involved in the study ,
the prognosis and risk of metastatic development were difficult to estimate considering the lack of knowledge for these rare diseases .
moreover , the novelty of hadrontherapy , which can potentially modify usual treatment strategies , could have led to the omission of this indication in some cases , in particular conditions unusually treated by radiotherapy as hepatic and biliary tumours .
these difficulties , along with the more sustained vigilance effort made by some groups relative to others , could account for the nonhomogeneous data collection and the observed difference between predictions and obtained results , despite the high motivation of the investigators .
furthermore , the reorganisations ( case of two major rcp clusters ) , changes of persons involved and the low frequency of cases to report , lead to a constant erosion of vigilance , requiring continuous action by the organiser .
however , some important institutions with their own recruitment targets did not wish to participate , which reduces the scope of our results . about the detailed conditions of the recruited cases , there are a large proportion of recurrent diseases as explained above , and some metastatic diseases have also been included according to defined characteristics : ( i ) the number of metastasis was limited ( 1 to 3 metastasis ) ; ( ii ) their very slow growing speed was not immediately threatening ; ( iii ) the possibility of effective treatment of these  pauci - metastatic  conditions , essentially by ablative procedures .
actually , the principle to treat , with curative intend , patients in such situation is more and more accepted by expert oncologists .
the estimated incidence of cancers , irrespective of type and location , eligible for treatment by hadrontherapy , for the study , that is , 8.5/100,000 individuals , is mildly higher than the reference incidence threshold of 6 cases/100,000 individuals , as defined in the orphanet international database of  rare diseases  .
this figure can be obviously explained by the fact that the incidence was calculated by adding the five major cancer categories and 34 different locations .
if one was to calculate the incidence for each of the disease types , their respective incidence would be significantly below the reference threshold of 6 cases/100,000 .
indeed , for our study , the minimum number of cases listed per disease is of 1 case and the maximum is of 7 cases .
table 4 . considering all of the difficulties and limitations of this preliminary phase of the study ,
the yield of approximately 25% notification , compared to the expected maximum , appears satisfactory . in the perspective of a ( necessary ) ramp up of a future hadrontherapy centre
, there is thus a sufficient population to initiate operation and to progressively establish recruitment for this centre , without immediately generating an insufficient offer effect .
future epidemiological studies will benefit from focusing on the characterisation of the metastatic development of diseases eligible for hadrontherapy .
all cancers have their own development pattern , and , in this respect , the literature provides few elements concerning diseases eligible for hadrontherapy .
this information should serve both to improve diagnosis procedures , medical care , and the surveillance of these rare diseases .  
this study of hadrontherapy healthcare decision networks in the rhne - alpes region , able to identify areas not properly covered by rcps , should enable us to analyse the potential effect of this lack on the outcome of the patients of these areas .  
they shed no light on posttreatment medical activity : follow - up visits , medical imaging , and other care beyond the irradiated activity per se .
one of the most valuable outcomes of this study has been to make the existence of some particularly rare diseases known and to provide information concerning an innovative treatment : hadrontherapy , whose existence will doubtless have a favourable effect on the very knowledge of these diseases .
an additional benefit of this approach has been to open the way for a new treatment system in a region of france that is home to approximately 10% of the country 's population . at last
, these elective indications will have to be validated by health authorities to register them as part of the good professional practices of oncology and give an equal chance to each patient to receive hadrontherapy through the well - established decision process of the rcps .
 
 context . 
 hadrontherapy is an innovative form of radiotherapy using beams of protons or carbon ions able to destroy some radio - resistant tumours . 
 because these tumours are highly specific amongst all cancerous tumours , it is impossible to determine the incidence of these diseases from surveillance registries . goal . to assess , within the rhne - alpes region , the incidence of cancers being hadrontherapy indications 
 . method . 
 prospective , multicentre continuous data collection during 1 year , by practitioners participating to multidisciplinary tumor board . 
 tumours are inoperable , radio resistant , at primary stage of development , or locally recurrent , with low metastatic potential 
 . results . 
 study involved 27 healthcare centres , 52 groups of specialist practitioners . 
 the estimated incidence of cancers eligible for hadrontherapy in the rhne - alpes region in 2010 , that is , for 34 locations in all , is of 8.5/100  000 inhabitants . 
 appraisal of the low potential of metastatic progression is impeded , because these are rare diseases , whose outcome is unfamiliar to investigators . 
 conclusion . 
 future epidemiological studies will need to focus on prognosis and on the metastatic progression rate of these diseases . 
 indeed , there are few information available on this subject in the literature that could be used to improve preventive measures , medical care , and the surveillance of these rare cancers . 
1. Scientific Context
2. Goals
3. Method
4. Results
5. Discussion
6. Conclusion